U.S. Blocks Venezuela From Funding Nicolas Maduro’s Legal Defense in New York Drug Trafficking Case 
Pokemon Pokopia Sells 2.2 Million Copies in Four Days, Boosting Nintendo Switch 2 Momentum 
Big Tech Turns to Debt Markets to Fund AI Infrastructure Boom 
UK Regulators Demand Social Media Platforms Strengthen Children's Age Verification 
FedEx Faces Class Action Lawsuit Over Tariff Refunds After Supreme Court Ruling 
Top Democrat Accuses DOJ of Withholding FBI Records in Trump-Epstein Investigation 
USTR Launches New Section 301 Trade Investigations After Supreme Court Tariff Ruling 
Peter Mandelson Arrested in London Amid Jeffrey Epstein Ties Investigation 
Renault's 2030 Global Growth Strategy: New Models, EV Expansion, and International Ambitions 
Microsoft Backs Anthropic in Legal Fight Against Pentagon's AI Blacklist 
Panama Cancels CK Hutchison Port Contracts, Grants Temporary Control to Maersk and MSC 
U.S. Senate Greenlights AI Chatbots for Official Staff Use 
Nintendo Stock Surges 10% as Pokémon Pokopia Breaks Sales Records 
ANZ and Westpac Forecast Two RBA Rate Hikes in March and May 2026 
BMW Warns of Further Earnings Decline in 2026 Amid Global Trade Pressures 
UBS Seeks Legal Protection Over Credit Suisse's Nazi-Era Banking Activities 
U.S. Supreme Court Strikes Down Trump Tariffs, Deepening Global Trade Uncertainty 
Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Sanofi, accusing the company of unlawfully incentivizing healthcare providers to prescribe its medications instead of competing alternatives. According to the attorney general’s office, Sanofi allegedly created service-based programs for healthcare professionals that effectively functioned as bribes, in violation of the Texas Health Care Program Fraud Prevention Act.
State officials claim these programs were designed to improperly influence prescribing decisions, potentially impacting fair competition and patient care within Texas healthcare programs. The lawsuit seeks more than $1 million in monetary relief, including civil penalties, as well as a court injunction to prevent any further alleged unlawful conduct.
Sanofi has strongly denied the allegations. In a public statement, the company asserted that its services are fully structured to comply with both federal and state regulations. Sanofi emphasized that the programs are intended to support patient care and improve health outcomes, not to sway physicians’ prescribing behavior. The company also stated that the state’s legal action does not reflect the merits of the case and confirmed it will vigorously defend itself in court.
This is not the first time Attorney General Paxton has taken legal action against major pharmaceutical companies. Previously, Texas sued Sanofi and Bristol-Myers Squibb, alleging they failed to disclose that their blood thinner Plavix was less effective for certain patients. In a separate case last year, the state filed a lawsuit against Eli Lilly, accusing the drugmaker of bribing healthcare providers to prescribe its top-selling medications, including GLP-1 drugs Mounjaro and Zepbound.
The latest lawsuit highlights Texas’ continued scrutiny of pharmaceutical industry practices, particularly regarding alleged healthcare fraud, drug marketing tactics, and compliance with state healthcare laws.
